» Articles » PMID: 38869884

Metabolic Profiling of Glioblastoma Stem Cells Reveals Pyruvate Carboxylase As a Critical Survival Factor and Potential Therapeutic Target

Overview
Journal Neuro Oncol
Specialties Neurology
Oncology
Date 2024 Jun 13
PMID 38869884
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Glioblastoma (GBM) is a highly aggressive tumor with unmet therapeutic needs, which can be explained by extensive intra-tumoral heterogeneity and plasticity. In this study, we aimed to investigate the specific metabolic features of Glioblastoma stem cells (GSC), a rare tumor subpopulation involved in tumor growth and therapy resistance.

Methods: We conducted comprehensive analyses of primary patient-derived GBM cultures and GSC-enriched cultures of human GBM cell lines using state-of-the-art molecular, metabolic, and phenotypic studies.

Results: We showed that GSC-enriched cultures display distinct glycolytic profiles compared with differentiated tumor cells. Further analysis revealed that GSC relies on pyruvate carboxylase (PC) activity for survival and self-renewal capacity. Interestingly, inhibition of PC led to GSC death, particularly when the glutamine pool was low, and increased differentiation. Finally, while GSC displayed resistance to the chemotherapy drug etoposide, genetic or pharmacological inhibition of PC restored etoposide sensitivity in GSC, both in vitro and in orthotopic murine models.

Conclusions: Our findings demonstrate the critical role of PC in GSC metabolism, survival, and escape to etoposide. They also highlight PC as a therapeutic target to overcome therapy resistance in GBM.

Citing Articles

LDH Isoenzyme and GAA-BSA Nanoparticles: A Novel Therapy Approach for Proneural Subtype Glioblastoma Multiforme.

Yang M, Han X, Li H, Du F, Feng C, Gong A J Cancer. 2025; 16(4):1101-1117.

PMID: 39895794 PMC: 11786042. DOI: 10.7150/jca.98452.


The Impact of Metabolic Rewiring in Glioblastoma: The Immune Landscape and Therapeutic Strategies.

Vijayanathan Y, Ho I Int J Mol Sci. 2025; 26(2).

PMID: 39859381 PMC: 11765942. DOI: 10.3390/ijms26020669.


Inhibiting glioblastoma stem cells by targeting pyruvate carboxylase: A novel therapeutic strategy with both opportunities and challenges.

Renoult O, Laurent-Blond M, Pecqueur C Neuro Oncol. 2024; 27(2):589-590.

PMID: 39724521 PMC: 11812024. DOI: 10.1093/neuonc/noae250.


Inhibiting glioblastoma stem cells by targeting pyruvate carboxylase: a novel therapeutic strategy with both opportunities and challenges.

Chen M, Mu G, Wu Y, Bjerkvig R, Wang H, Wang D Neuro Oncol. 2024; 27(2):586-588.

PMID: 39724389 PMC: 11812023. DOI: 10.1093/neuonc/noae249.


Agonists and Inhibitors of the cGAS-STING Pathway.

Yu X, Cai L, Yao J, Li C, Wang X Molecules. 2024; 29(13).

PMID: 38999073 PMC: 11243509. DOI: 10.3390/molecules29133121.

References
1.
Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

2.
Cappel D, Deja S, Duarte J, Kucejova B, Inigo M, Fletcher J . Pyruvate-Carboxylase-Mediated Anaplerosis Promotes Antioxidant Capacity by Sustaining TCA Cycle and Redox Metabolism in Liver. Cell Metab. 2019; 29(6):1291-1305.e8. PMC: 6585968. DOI: 10.1016/j.cmet.2019.03.014. View

3.
Lin Q, He Y, Wang X, Zhang Y, Hu M, Guo W . Targeting Pyruvate Carboxylase by a Small Molecule Suppresses Breast Cancer Progression. Adv Sci (Weinh). 2020; 7(9):1903483. PMC: 7201266. DOI: 10.1002/advs.201903483. View

4.
Neftel C, Laffy J, Filbin M, Hara T, Shore M, Rahme G . An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell. 2019; 178(4):835-849.e21. PMC: 6703186. DOI: 10.1016/j.cell.2019.06.024. View

5.
Bosc C, Saland E, Bousard A, Gadaud N, Sabatier M, Cognet G . Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia. Nat Cancer. 2022; 2(11):1204-1223. DOI: 10.1038/s43018-021-00264-y. View